{
"id":"mk19_a_gi_q004",
"number":4,
"bookId":"gi",
"correctAnswer":"B",
"title":"Question 4",
"stimulus":[
{
"type":"p",
"hlId":"c4f121",
"children":[
"A 30-year-old woman is evaluated at a new-patient visit. She was born in Somalia and immigrated to the United States 2 years ago."
]
},
{
"type":"p",
"hlId":"f78abf",
"children":[
"On physical examination, vital signs and other findings are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"62ea29",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Aminotransferase, alanine (ALT)",
"children":[
"Alanine aminotransferase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"260e35",
"class":"cell text l",
"children":[
"24 U/L"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"7e4439",
"class":"cell text l",
"children":[
"Hepatitis B virus DNA"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a97c7b",
"class":"cell text l",
"children":[
"Undetected"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"40a0c3",
"class":"cell text l",
"children":[
"Hepatitis B core antigen IgG antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"3a242b",
"class":"cell text l",
"children":[
"Hepatitis B surface antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2ff2e8",
"class":"cell text l",
"children":[
"Hepatitis B surface antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"20cc3d",
"class":"cell text l",
"children":[
"Hepatitis B e antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"5b1fdc",
"class":"cell text l",
"children":[
"Hepatitis B e IgG antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"3b30f6",
"children":[
"Which of the following best describes this patient's phase of hepatitis B virus infection?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Immune active"
}
},
{
"letter":"B",
"text":{
"__html":"Immune control"
}
},
{
"letter":"C",
"text":{
"__html":"Immune tolerant"
}
},
{
"letter":"D",
"text":{
"__html":"Reactivation"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2cda71",
"children":[
"The four phases of chronic hepatitis B virus (HBV) infection are differentiated on the basis of immune response: immune tolerant, immune active, immune control, and reactivation."
]
},
{
"type":"keypoint",
"hlId":"9c9765",
"children":[
"Patients in the immune control phase of chronic HBV infection, also known as inactive chronic HBV infection, generally do not require treatment."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"002690",
"children":[
"This patient is in the immune control phase of chronic hepatitis B virus (HBV) infection (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). Screening for chronic HBV infection is indicated in persons born or raised in regions with high rates of HBV infection, including Asia, Africa, the South Pacific, European Mediterranean countries, Eastern Europe, most of South America, Honduras, Guatemala, and the Middle East (except Israel and Cyprus). Screening will detect those who may benefit from treatment. Treatment is offered to selected patients in the immune active phase of infection. The four phases of infection are categorized on the basis of immune response to the virus: immune tolerant, immune active, immune control, and reactivation. The immune control phase of chronic HBV infection is also known as inactive chronic HBV infection. The immune control phase is characterized by normal serum alanine aminotransferase (ALT) measurement, indicating absence of liver inflammation; positive results for hepatitis B core (HBc) antigen IgG antibody, indicating previous infection; hepatitis B e antigen (HBeAg)–negative and anti-HBe–positive serology, indicating lack of viral replication and infectivity; and HBV DNA level less than 2000 U/mL, indicating immune control of viral replication and infection. This patient meets all the criteria for the immune control phase of chronic HBV infection. She does not require treatment."
]
},
{
"type":"p",
"hlId":"255bca",
"children":[
"The immune active phase of chronic HBV infection (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is characterized by evidence of liver inflammation (elevated ALT level) and uncontrolled infection (HBV DNA >2000 U/mL). HBeAg may be positive or negative in this phase. Depending on other factors, treatment may be indicated."
]
},
{
"type":"p",
"hlId":"5e73dc",
"children":[
"The immune tolerant phase (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is acquired through vertical transmission. In this phase, HBeAg is positive, anti-HBeAg is negative, ALT level is normal, but HBV DNA level exceeds 1 million U/mL. Treatment is not recommended in this phase."
]
},
{
"type":"p",
"hlId":"7c86c6",
"children":[
"The reactivation phase (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is characterized by loss of HBV immune control. It is recognized by a rising HBV DNA level compared with baseline or seroconversion of hepatitis B surface antigen (HBsAg) from negative to positive in patients who were previously HBsAg negative and anti-HBc positive. Reactivation may be the result of immunosuppression with immune modulators, cytotoxic chemotherapy, and drugs that deplete B lymphocytes, such as rituximab. Prophylactic treatment is typically recommended for select patients in the immune control phase who are at risk for reactivation."
]
}
],
"relatedSection":"mk19_a_gi_s6_2_2",
"objective":{
"__html":"Categorize the phase of chronic hepatitis B virus infection."
},
"references":[
[
"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29405329",
"target":"_blank"
},
"children":[
"PMID: 29405329"
]
},
" doi:10.1002/hep.29800"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":22,
"B":41,
"C":29,
"D":8,
"E":0
},
"hlIds":[
"c4f121",
"f78abf",
"a462a3",
"62ea29",
"260e35",
"7e4439",
"a97c7b",
"40a0c3",
"328929",
"3a242b",
"ffb935",
"2ff2e8",
"328929",
"20cc3d",
"ffb935",
"5b1fdc",
"328929",
"3b30f6",
"2cda71",
"9c9765",
"002690",
"255bca",
"5e73dc",
"7c86c6"
]
}